A First Evaluation of OMNI®, A New Device for Continuous Renal Replacement Therapy.

Abstract

BACKGROUND:

Omni® (B. Braun, Germany) is a new-generation, continuous renal replacement therapy (CRRT) machine designed to improve user interface, minimize downtime and optimize renal dose delivery. It was never tested in humans.

METHODS:

We used Omni® to provide CRRT in 10 critically ill patients. We collected therapy data, metabolic parameters and evaluated user's satisfaction with a survey.

RESULTS:

CRRT was delivered using Omni® in CVVH-heparin (6 patients) and CVVHD-citrate (4 patients) modes for a total duration of 617.7 h. No adverse event was observed. The mean filter life was 22.8 (CVVH-heparin) and 33.5 (CVVHD-citrate) h. Alarms-related downtime corresponded to 5.9% of total therapy time. Delivered renal dose was 96.6% of prescribed. Satisfactory metabolic control and fluid removal were achieved. Overall, users evaluated interface, design and usability as excellent.

CONCLUSION:

CRRT in CVVH-heparin and CVVHD-citrate modes was provided using Omni® in a safe and efficient way for 10 critically ill patients. Video Journal Club 'Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=451053.

• Authors: Pierre Schläpfer, Jean-Daniel Durovray, Valery Plouhinec, Cristiano Chiappa, Rinaldo Bellomo, Antoine Schneider
• Journal: Blood purification (Blood Purif) Vol. 43 Issue 1-3 Pg. 11-17 ( 2017) ISSN: 1421-9735 [Electronic] Switzerland
• PMID: 27846630 (Publication Type: Evaluation Study, Journal Article)
• Copyright: © 2016 S. Karger AG, Basel.

Chemical References

• Citric Acid
• Heparin

Topics

• Citric Acid (therapeutic use)
• Critical Illness
• Equipment Design
• Heparin (therapeutic use)
• Humans
• Patient Safety
• Renal Replacement Therapy (instrumentation)
• Time Factors